Sequenom Shares Fall After Revised Test Data | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Sequenom fell around 10 percent in Wednesday trade, a day after the firm released additional data from a study on its prenatal screening technology for Down syndrome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.